Donate to save lives this Breast Cancer Awareness Month.
A study of neoadjuvant nivolumab + palbociclib + anastrozole in post-menopausal women and men with primary breast cancer.
Who is it for?
You may be eligible for this study if you meet the below criteria:
Patients will receive either (1) nivolumab + palbociclib + anastrozole (ANZ); (2) palbociclib + ANZ then nivolumab + palbociclib + ANZ; or (3) palbociclib + ANZ.
Want to access a trial that's not in your area? It's not always possible, but if you're interested, email us at email@example.com
Are we out of date? If you have updated or new information about a trial, we’d be grateful if you’d share it with us – email your update to firstname.lastname@example.org